OCT Oncology ™ is a dedicated solutions package aimed at helping pharma from early to late stage oncology treatment development. OCT Clinical is a full-service oncology CRO with a professional network of 300 leading oncology clinics in 10 countries, led by a highly-skilled clinical team. This year, we carried out our 80th oncology study and have recruited 35,466 patients.
RFP übermittelnWe provide a full range of high-quality clinical trial services for Phase I-IV and BE studies. We offer both full-service clinical study engagements and stand alone services in a number of therapeutic areas.
* patients / site / month
Succeeding in target treatment development dictates the use of innovative methods to quickly identify and deliver the right therapy to the right patient. Within our vast portfolio of oncology studies, we are proud to offer adequate expertise in immuno-oncology studies. Look at the snapshot with our most prominent cases in this area.
* Number of patients recruited by OCT Clinical
We never settle for a compromise when choosing between quality, timeline and budget. We always deliver the best on all three.
Irina Petrova
Director of Clinical Operations
OCT Clinical is privileged to support global pharmaceutical companies and biotechs, and with this experience we can help you follow the right steps towards faster treatment approvals, so medicines can reach patients more rapidly.
Reach out to us to learn more about how our approach, experience, investigator relationships, bid transparency and flexibility deliver success for our clients.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
